Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	94415
Country	China

Received	2024-03-18 12:05
Peer-Review Started	2024-03-18 12:05
To Make the First Decision
Return for Revision	2024-05-01 20:33
Revised	2024-05-16 02:14
Second Decision	2024-05-28 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-05-28 07:25
Articles in Press	2024-05-28 07:25
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-06-12 06:47
Typeset the Manuscript	2024-06-14 00:43
Publish the Manuscript Online	2024-07-12 15:55

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Ke Wang, Xin Yang, Tong-Han Yao, Peng-Xian Tao, Guan-Jun Jia, De-Xian Sun, Lin Yi and Yuan-Hui Gu
ORCID	Author(s) ORCID Number Xiao-Ke Wang http://orcid.org/0009-0003-5734-1762 Yuan-Hui Gu http://orcid.org/0000-0003-0364-3012
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 82160842 Clinical Research Project of Research Fund of Gansu Provincial People's Hospital 23GSSYD-17
Corresponding Author	Yuan-Hui Gu, Doctor, Chief Doctor, Surgeon, Surgical Oncologist, Department of General Surgery, Gansu Provincial Hospital, No.204 Donggang West Road, Lanzhou 730000, Gansu Province, China. guyuanh@163.com
Key Words	Gastrointestinal stromal tumor; M2 macrophage; Inflammatory response; Programmed death receptor-1; Programmed death ligand-1; Imatinib; Immunotherapy; Targeted therapy
Core Tip	The place of imatinib in the treatment of gastrointestinal stromal tumor (GIST) is indisputable, but it has some limitations and is not accepted by all patients. In this review, we summarize the interaction between M2 macrophages and the programmed death receptor-1/programmed death ligand-1 pathway, which can improve the efficacy of imatinib by reactivating or enhancing the antitumor effect of the host immune system, and provide new ideas for immunotherapy of GIST.
Publish Date	2024-07-12 15:55
Citation	<p>Wang XK, Yang X, Yao TH, Tao PX, Jia GJ, Sun DX, Yi L, Gu YH. Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor. <i>World J Gastrointest Oncol</i> 2024; 16(7): 2915-2924</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i7/2915.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i7.2915

Full Article (PDF)	WJGO-16-2915-with-cover.pdf
Manuscript File	94415-Review-Filipodia.docx
Answering Reviewers	94415-answering-reviewers.pdf
Audio Core Tip	94415-audio.m4a
Conflict-of-Interest Disclosure Form	94415-conflict-of-interest-statement.pdf
Copyright License Agreement	94415-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	94415-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	94415-non-native-speakers.pdf
Peer-review Report	94415-peer-reviews.pdf
Scientific Misconduct Check	94415-scientific-misconduct-check.png
Scientific Editor Work List	94415-scientific-editor-work-list.pdf
CrossCheck Report	94415-crosscheck-report.pdf